Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
The story is part of ongoing coverage in the AI & Technology category, reported by TechCrunch and shared here for readers following developments in this space.
Diajem Global Black News will continue to follow this story and update readers as more information becomes available. For the original reporting and further detail, see the source link below.
Source: TechCrunch | Published: Sat, 29 Aug 2026 17:36:47
Leave a Reply